Literature DB >> 6175222

Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor.

S H Phan, R S Thrall.   

Abstract

A single dose of cobra venom factor, a known, potent depletor of serum complement, has recently been reported to be highly effective in inhibiting lung collagen deposition at 7 days after bleomycin treatment. The present study shows that this is associated with suppression of the bleomycin-induced increase in collagen synthesis, down to virtually normal levels. There is also a concomitant reduction in tissue free proline pool size. No significant effects are noted in noncollagenous protein synthetic rates. This inhibitory effect is not seen at 30 days after bleomycin and is correlated with a return to normal levels of serum complement hemolytic activity. These data suggest an important role for complementary activity in the lung's fibrotic response to bleomycin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175222      PMCID: PMC1915983     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins.

Authors:  B Peterkofsky; R Diegelmann
Journal:  Biochemistry       Date:  1971-03-16       Impact factor: 3.162

2.  Pulmonary toxicity due to bleomycin. Report of a case.

Authors:  H F Krous; W B Hamlin
Journal:  Arch Pathol       Date:  1973-06

3.  Interstitial pneumonitis associated with bleomycin therapy.

Authors:  M A Luna; C W Bedrossian; B Lichtiger; P A Salem
Journal:  Am J Clin Pathol       Date:  1972-11       Impact factor: 2.493

4.  [Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat].

Authors:  J L Maillard; R M Zarco
Journal:  Ann Inst Pasteur (Paris)       Date:  1968-06

5.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

6.  On the nature of immunological tolerance.

Authors:  M M Azar; E J Yunis; P J Pickering; R A Good
Journal:  Lancet       Date:  1968-06-15       Impact factor: 79.321

7.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

8.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

9.  Liver collagen synthesis in murine schistosomiasis.

Authors:  M A Dunn; M Rojkind; K S Warren; P K Hait; L Rifas; S Seifter
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

10.  Experimentally induced bleomycin sulfate pulmonary toxicity: histopathologic and ultrastructural study in the pheasant.

Authors:  C W Bedrossian; S D Greenberg; D H Yawn; R M O'Neal
Journal:  Arch Pathol Lab Med       Date:  1977-05       Impact factor: 5.534

View more
  12 in total

1.  Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis.

Authors:  Hongmei Gu; Elizabeth A Mickler; Oscar W Cummings; George E Sandusky; Daniel J Weber; Adam Gracon; Trent Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2014-06-23       Impact factor: 5.191

Review 2.  New strategies for treatment of pulmonary fibrosis.

Authors:  S H Phan
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

Review 3.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

4.  Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

Authors:  Heather G Leach; Izabela Chrobak; Rong Han; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

5.  Analysis of renal fibrosis in a rabbit model of crescentic nephritis.

Authors:  G Downer; S H Phan; R C Wiggins
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.

Authors:  Tsukasa Okamoto; Susan K Mathai; Corinne E Hennessy; Laura A Hancock; Avram D Walts; Adrianne L Stefanski; Kevin K Brown; David A Lynch; Gregory P Cosgrove; Steve D Groshong; Carlyne D Cool; Marvin I Schwarz; Nirmal K Banda; Joshua M Thurman; Ivana V Yang; V Michael Holers; David A Schwartz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-22       Impact factor: 5.464

7.  Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis.

Authors:  S H Phan; J Varani; D Smith
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 8.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

9.  Modulation of bleomycin-induced pulmonary fibrosis in the BALB/c mouse by cyclophosphamide-sensitive T cells.

Authors:  D J Schrier; S H Phan
Journal:  Am J Pathol       Date:  1984-08       Impact factor: 4.307

10.  Complement inhibition decreases early fibrogenic events in the lung of septic baboons.

Authors:  Robert Silasi-Mansat; Hua Zhu; Constantin Georgescu; Narcis Popescu; Ravi S Keshari; Glenn Peer; Cristina Lupu; Fletcher B Taylor; Heloise Anne Pereira; Gary Kinasewitz; John D Lambris; Florea Lupu
Journal:  J Cell Mol Med       Date:  2015-09-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.